All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Is venetoclax combined with low dose cytarabine and actinomycin D safe and effective in patients with AML who relapse after allo-HSCT?
Bookmark this article
During the 25th European Hematology Association (EHA) Annual Congress, the AML Hub spoke to Andrius Žučenka, Vilnius University Hospital Santaros Klinikos, Vilnius, LT. We asked, Is venetoclax + low dose cytarabine (ara-C) + actinomycin D safe and effective in patients with AML following relapse to allogeneic hematopoietic stem cell transplantation (allo-HSCT)?
Is venetoclax + low dose ara-C + actinomycin D safe and effective in patients with AML?
Venetoclax in combination with low dose ara-C has demonstrated modest results in patients who relapse after allo-HSCT, with median overall survival rates between 3–6 months. Overexpression of the anti-apoptotic protein, MCL-1, is believed to play a significant role in patient resistance to venetoclax.
This interview outlines the study evaluating the ability of actinomycin D, identified as having MCL-1 inhibiting properties, in combination with venetoclax + low dose ara-C to improve survival outcomes of patients with AML who relapse after allo-HSCT.
More about...
Your opinion matters
14 votes - 2 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox